Detalles de la búsqueda
1.
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.
Int J Cancer
; 148(10): 2557-2570, 2021 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33348420
2.
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Lancet Oncol
; 20(11): 1587-1601, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31575503
3.
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Invest New Drugs
; 36(6): 1016-1025, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29611022
4.
Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.
Invest New Drugs
; 30(2): 662-71, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21188466
5.
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
Clin Lung Cancer
; 22(5): 449-460, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33895103
6.
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.
Cancer Manag Res
; 13: 6207-6218, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34408488
7.
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Adv Ther
; 38(1): 350-365, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33123968
Resultados
1 -
7
de 7
1
Próxima >
>>